Form 4: Karyopharm Therapeutics Executive Sohanya Cheng Reports Stock Sale to Cover Tax Obligations
SEC Form 4 Filing
Sohanya Cheng, EVP & Chief Commercial Officer of Karyopharm Therapeutics, reports selling shares to cover withholding tax liabilities related to vested restricted stock units.
Summary
- On September 4, 2024, Sohanya Cheng, EVP & Chief Commercial Officer of Karyopharm Therapeutics Inc., reported a sale of 5,356 shares of common stock at a price of $0.7218 per share.
- The sale was executed under a pre-arranged automatic sale plan adopted on June 7, 2022, to cover withholding tax obligations arising from the vesting of restricted stock units.
- Following the transaction, Cheng directly owns 404,051 shares of Karyopharm Therapeutics Inc.
- This includes 15,898 shares acquired under the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan on April 30, 2024.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a routine stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a routine Form 4 filing, indicating insider activity related to stock compensation and tax obligations. Such filings are common and provide transparency into executive stock transactions.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders due to the increased supply of shares, but the effect is likely minimal given the relatively small volume of shares sold.
Key Dates
| Date | Description |
|---|---|
| June 7, 2022 | Date of adoption of the durable automatic sale instruction plan. |
| April 30, 2024 | Date of acquisition of 15,898 shares under the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan. |
| September 4, 2024 | Date of the reported stock sale transaction. |
| September 5, 2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.